- Home
- MP vs APGE Comparison
MP vs APGE Comparison
Compare MP & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MP
- APGE
- Stock Information
- Founded
- MP 2017
- APGE 2022
- Country
- MP United States
- APGE United States
- Employees
- MP N/A
- APGE N/A
- Industry
- MP Metal Mining
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MP Basic Materials
- APGE Health Care
- Exchange
- MP Nasdaq
- APGE Nasdaq
- Market Cap
- MP 2.7B
- APGE 3.0B
- IPO Year
- MP N/A
- APGE 2023
- Fundamental
- Price
- MP $20.96
- APGE $37.06
- Analyst Decision
- MP Buy
- APGE Strong Buy
- Analyst Count
- MP 11
- APGE 5
- Target Price
- MP $21.55
- APGE $83.50
- AVG Volume (30 Days)
- MP 3.1M
- APGE 488.2K
- Earning Date
- MP 02-20-2025
- APGE 03-04-2025
- Dividend Yield
- MP N/A
- APGE N/A
- EPS Growth
- MP N/A
- APGE N/A
- EPS
- MP N/A
- APGE N/A
- Revenue
- MP $184,074,000.00
- APGE N/A
- Revenue This Year
- MP N/A
- APGE N/A
- Revenue Next Year
- MP $72.90
- APGE N/A
- P/E Ratio
- MP N/A
- APGE N/A
- Revenue Growth
- MP N/A
- APGE N/A
- 52 Week Low
- MP $10.02
- APGE $31.75
- 52 Week High
- MP $24.01
- APGE $72.29
- Technical
- Relative Strength Index (RSI)
- MP 61.51
- APGE 32.29
- Support Level
- MP $19.93
- APGE $36.48
- Resistance Level
- MP $21.14
- APGE $42.98
- Average True Range (ATR)
- MP 1.04
- APGE 2.92
- MACD
- MP 0.42
- APGE -0.99
- Stochastic Oscillator
- MP 90.91
- APGE 4.12
About MP MP Materials Corp.
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.